BiotechTube

SHR4640 dose1 + Febuxostat dose2

Phase 1UNKNOWN
0 watching 0 views this weekπŸ’€ Quiet
33
Hype Score

Development Stage

βœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperuricemia

Conditions

Hyperuricemia

Trial Timeline

Oct 14, 2019 β†’ Jun 30, 2020

NCT ID
NCT04157959

About SHR4640 dose1 + Febuxostat dose2

SHR4640 dose1 + Febuxostat dose2 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Hyperuricemia. The current trial status is unknown. This product is registered under clinical trial identifier NCT04157959. Target conditions include Hyperuricemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04157959Phase 1UNKNOWN

Competing Products

20 competing products in Hyperuricemia

See all competitors
ProductCompanyStageHype Score
SHR4640 dose1 plus Febuxostat dose1 + SHR4640 dose1 plus Febuxostat dose2 + SHR4640 dose2 plus Febuxostat dose3Jiangsu Hengrui MedicinePhase 2
52
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 1
33
Placebo + SHR4640 + benzbromaroneJiangsu Hengrui MedicinePhase 2
52
SHR4640 tablet + SHR4640 tablet + febuxostat tablet + SHR4640 placebo tabletJiangsu Hengrui MedicinePhase 2
52
SHR4640Jiangsu Hengrui MedicinePhase 1
33
repaglinide; midazolam; SHR4640 + repaglinide; midazolam; SHR4640; SHR4640 placebo + repaglinide; midazolam; SHR4640 placeboJiangsu Hengrui MedicinePhase 1
33
SHR4640 + placeboJiangsu Hengrui MedicinePhase 1
33
SHR4640 οΌ›Febuxostat + SHR4640 ; Febuxostat + SHR4640 + SHR4640 + FebuxostatJiangsu Hengrui MedicinePhase 2
52
SHR4640 + SHR4640Jiangsu Hengrui MedicinePhase 1
33
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
77
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
77
SHR4640 + PlaceboJiangsu Hengrui MedicinePhase 1
33
Verinurad + Febuxostat + DapagliflozinAstraZenecaPhase 2
52
Verinurad 9 mg+Febuxostat 80 mg + PlaceboAstraZenecaPhase 2
52
RDEA3170 + Allopurinol + PlaceboAstraZenecaPhase 2
52
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
41
KUX-1151Kissei PharmaceuticalPhase 2
51
Arhalofenate + Febuxostat + ColchicineGilead SciencesPhase 2
51
Arhalofenate + Arhalofenate + Placebo comparator + ColchicineGilead SciencesPhase 2
51
FYU-981 + FebuxostatMochida PharmaceuticalPhase 3
76

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85